tives shared their criteria for determining whether to license and develop an academic asset or drug candidate
Federal Government Resources Panel: Employees from the National Institutes of Health/National Institute for Neurological Disease and Stroke outlined resources available for brain tumor researchers, in terms of both funding and advice, to translate discoveries into therapies
The panels discussed issues ranging from creating data packages big enough to show translatability and reproducibility (close to 70% of research fails to reproduce outside the original academic lab), to de-risking and simplifying the market for brain tumor drug development. Panelists also offered candid advice for researchers.
"If you're an academic looking to potentially take a program or an asset from your lab and trying to spin it out into a company, it's important as you begin to look at possible investors that you understand what their investment strategy is," said Michael Gutch, PhD, MD, and Managing Director of MedImmune Ventures.
"We invest in people we like to invest with,” added Neil Exter, Partner, Third Rock Ventures. “It's good to develop relationships with your friendly VCs in the nearer term, or over time."
Following the advice and subsequent discussions from Industry and government’s perspective, National Brain Tumor Society-funded academic researchers showcased their latest drug candidates in hopes of obtaining funding to move their asset toward clinical trials. Out of the four drug candidates presented, two of the corresponding researchers have already been in deeper discussions with Industry representatives that were on hand to seek licensing and development partnerships.
Nearly 700,000 people in the U.S. are living with a brain tumor, and close to 14,000 people will die because of the disease this year alone. Only one out of three adults diagnosed with a malignant brain tu
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA2
. Advancing Preclinical Predictions, Making Faster Clinical Decisions with Cancer Models and Preclinical Imaging - World Pharma Congress this June in Philadelphia3
. 4th Annual Advancing Global Clinical Trials Conference is Announced4
. Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury Biomarkers5
. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments6
. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine7
. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research8
. Medical Device and Drug Research, New Life Science Webinar Hosted by Xtalks9
. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz10
. Elliott Broidy Expands Role in Los Angeles Civics with Support of Stem Cell Research Program11
. New Research on Rapid Identification and Strain Typing of Salmonella in Food to Be Presented at IAFP